Astaxanthin - Mera

Drug Profile

Astaxanthin - Mera

Alternative Names: AstaFactor

Latest Information Update: 20 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mera Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Xanthophylls
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cardiovascular disorders; Exercise-induced asthma; Macular degeneration

Most Recent Events

  • 20 Sep 2002 Aquasearch is now called Mera Pharmaceuticals
  • 11 Jun 2002 No development reported - Clinical-Phase-Unknown for Cardiovascular disorders in USA (PO)
  • 11 Jun 2002 No development reported - Clinical-Phase-Unknown for Exercise-induced asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top